{"transactions":[{"id":813846,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":false,"shares":157417,"price":0.07,"value":11019.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":110000,"derivative":{"exercise_price":0.07,"exercise_date":"2026-03-31","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":156086},"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813845,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-10","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on March 10, 2026; the remaining shares will vest monthly, starting on June 10, 2026, subject to the reporting person's continued service on each such date, until the award is fully vested on March 10, 2029."}],"balance_after":110000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-03-09","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813844,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-31","kind":"exercise","planned":false,"acquired":true,"shares":157417,"price":0.07,"value":11019.19,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 31, 2026, Dr. Imhoff converted $11,019.18 outstanding under a September 25, 2025 Convertible Promissory Note into 157,417 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $1,019.18 of accrued interest. Following the reported conversion, $110,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":21252673,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813843,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":21095256,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813842,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series F Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":false,"shares":10,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 26, 2026, Mr. Imhoff converted 10 shares of Series F preferred stock into 40,000 shares of common stock. The Series F preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":813841,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-07T19:14:37.000Z","date":"2026-03-26","kind":"other","planned":false,"acquired":true,"shares":2157,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.2773."}],"balance_after":21055256,"source":{"system":"sec-edgar","filing":"0001477932-26-002052","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226002052/form4.xml","form_type":"4"}},{"id":847121,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":false,"shares":156086,"price":0.07,"value":10926.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":120000,"derivative":{"exercise_price":0.07,"exercise_date":"2026-02-27","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":156086},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847120,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.2,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847119,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":500000,"derivative":{"exercise_price":0.2,"exercise_date":"2026-02-25","expiration_date":"2026-02-25","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847118,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.5,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847117,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":500000,"derivative":{"exercise_price":0.65,"exercise_date":"2026-02-25","expiration_date":"2027-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847116,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":false,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":0,"derivative":{"exercise_price":0.65,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847115,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-02","kind":"exercise","planned":false,"acquired":false,"shares":312720,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":130000,"derivative":{"exercise_price":0.07,"exercise_date":"2026-01-30","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":312720},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847114,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Promissory Note","published_at":"2026-03-12T23:52:25.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":false,"shares":195460,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"shares","element":"transactionShares","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":150000,"derivative":{"exercise_price":0.07,"exercise_date":"2025-11-28","expiration_date":"2027-02-28","underlying":"Common Stock","underlying_shares":195460},"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847113,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"exercise","planned":false,"acquired":true,"shares":156086,"price":0.07,"value":10926.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":21053099,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847112,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"other","planned":false,"acquired":true,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":20897013,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847111,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-27","kind":"other","planned":false,"acquired":false,"shares":100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847110,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-25","kind":"other","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027."}],"balance_after":20497013,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847109,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-02-02","kind":"exercise","planned":false,"acquired":true,"shares":312720,"price":0.07,"value":21890.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":19997013,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847108,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2026-01-05","kind":"other","planned":false,"acquired":true,"shares":25338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157."}],"balance_after":19684293,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":847107,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-12T23:52:25.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":true,"shares":195460,"price":0.07,"value":13682.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note."}],"balance_after":19658955,"source":{"system":"sec-edgar","filing":"0001477932-26-001320","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793226001320/form4.xml","form_type":"4"}},{"id":1047120,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":166667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":191667,"derivative":{"exercise_price":0.25,"exercise_date":"2025-08-29","expiration_date":"2029-08-29","underlying":"Common Stock","underlying_shares":166667},"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047119,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-29","kind":"purchase","planned":false,"acquired":true,"shares":166667,"price":0.18,"value":30000.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On August 29, 2025, the Company entered into a Securities Purchase Agreement with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $30,000, 166,667 units, each unit consisting of one share of common stock and one warrant to purchase up to 166,667 shares of common stock (the \"August Warrants\"). The August Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.25 per share."}],"balance_after":19463495,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047118,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":19296828,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047117,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":false,"shares":300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 21, 2025, Mr. Imhoff converted 300 shares of Series E preferred stock into 1,200,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1047116,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-09-05T20:16:44.000Z","date":"2025-08-21","kind":"other","planned":false,"acquired":true,"shares":104448,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.2298."}],"balance_after":18096828,"source":{"system":"sec-edgar","filing":"0001477932-25-006528","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225006528/form4.xml","form_type":"4"}},{"id":1114133,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-06-12T23:20:23.000Z","date":"2025-06-03","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on June 3, 2025; the remaining shares will vest monthly, starting on September 3, 2025, subject to the reporting person's continued service on each such date, until the award is fully vested on June 2, 2028."}],"balance_after":110000,"derivative":{"exercise_price":0.14,"expiration_date":"2035-06-02","underlying":"Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001477932-25-004559","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004559/form4.xml","form_type":"4"}},{"id":1136042,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":1263069,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":263069},"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136041,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":1000000,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136040,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-04-10","kind":"other","planned":false,"acquired":true,"shares":6365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F7","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":17992380,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136039,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"price":0.1,"value":26306.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":17986015,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136038,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":0.1,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":17722946,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136037,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series E Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-13","kind":"purchase","planned":false,"acquired":true,"shares":150,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 13, 2025, for a purchase price of $30,000, Mr. Imhoff purchased 150 shares of Series E preferred stock from a third party. The shares have a conversion price of $0.25 and a stated value of $1,000."}],"balance_after":400,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136036,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":true,"shares":2258690,"price":0.1266,"value":285950.154,"ownership":{"direct":true},"balance_after":16722946,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136035,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":false,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136034,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":286,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136033,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":4801500,"price":0.5,"value":2400750.0,"ownership":{"direct":true},"balance_after":14464256,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136032,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C2 Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":2400.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136031,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":9662756,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1136030,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series D Stock","published_at":"2025-05-23T18:16:41.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-004137","document":"form4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225004137/form4a.xml","form_type":"4/A","original_submission_date":"2025-04-17"}},{"id":1170273,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":1263069,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":263069},"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170272,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."}],"balance_after":1000000,"derivative":{"exercise_price":0.13,"exercise_date":"2025-03-18","expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170271,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-04-10","kind":"other","planned":false,"acquired":true,"shares":6365,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.0943."}],"balance_after":17992380,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170270,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":263069,"price":0.1,"value":26306.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"In connection with the March Purchase Agreement, the Company entered into an exchange agreement with Dr. Imhoff, whereby Dr. Imhoff agreed to exchange a $25,000 note payable and accrued interest of $1,307 for 263,069 units as described above."}],"balance_after":17986015,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170269,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-18","kind":"purchase","planned":false,"acquired":true,"shares":1000000,"price":0.1,"value":100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 18, 2025, the Company entered into a Securities Purchase Agreement (the \"March Purchase Agreement\") with Dr. Imhoff, pursuant to which the Company agreed to sell, for a total price of $100,000, 1,000,000 units, each unit consisting of one share of common stock and one warrant to purchase up to 1,000,000 shares of common stock (the \"March Warrants\"). The March Warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.13 per share."}],"balance_after":17722946,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170268,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":true,"shares":2258690,"price":0.1266,"value":285950.154,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":16722946,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170267,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-11","kind":"other","planned":false,"acquired":false,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170266,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-07","kind":"purchase","planned":false,"acquired":true,"shares":286,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 7, 2025, for a purchase price of $112,934.50, Mr. Imhoff purchased 286 shares of Series C preferred stock from a third party. The shares had a conversion price of $0.1266, and on March 11, 2025 were converted to 2,258,690 common shares."}],"balance_after":286,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170265,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":4801500,"price":0.5,"value":2400750.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."}],"balance_after":14464256,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170264,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series C2 Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":2400.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On March 6, 2025, Mr. Imhoff signed an exchange agreement to convert shares of Series C2 preferred stock at $0.50 conversion prices. For 2,400.75 Series C2 preferred shares, Mr. Imhoff received 4,801,500 common shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170263,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":true,"shares":900000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":9662756,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1170262,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Preferred Series D Stock","published_at":"2025-04-17T20:06:40.000Z","date":"2025-03-06","kind":"other","planned":false,"acquired":false,"shares":300,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 6, 2025, Mr. Imhoff converted 300 shares of Series D preferred stock into 900,000 shares of common stock. The Series D preferred stock had a stated value of $750 and $0.25 exercise price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001477932-25-002818","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225002818/form4.xml","form_type":"4"}},{"id":1265000,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-02-18T11:04:39.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":35312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1593."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1593."}],"balance_after":8762756,"source":{"system":"sec-edgar","filing":"0001477932-25-001072","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793225001072/form4.xml","form_type":"4"}},{"id":1324684,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-12-20T23:29:20.000Z","date":"2024-12-18","kind":"purchase","planned":false,"acquired":true,"shares":1615385,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share."}],"balance_after":1615385,"derivative":{"exercise_price":0.18,"exercise_date":"2024-12-18","expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":1615385},"source":{"system":"sec-edgar","filing":"0001477932-24-008256","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224008256/form4.xml","form_type":"4"}},{"id":1324683,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-20T23:29:20.000Z","date":"2024-12-18","kind":"purchase","planned":false,"acquired":true,"shares":1615385,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 18, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $210,000, the Company issued 1,615,385 shares of its common stock and warrants to purchase an aggregate of 1,615,385 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.18 per share."}],"balance_after":8727444,"source":{"system":"sec-edgar","filing":"0001477932-24-008256","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224008256/form4.xml","form_type":"4"}},{"id":1381610,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-25T16:23:52.000Z","date":"2024-10-15","kind":"other","planned":false,"acquired":true,"shares":36161,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1556."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1556."}],"balance_after":7112059,"source":{"system":"sec-edgar","filing":"0001477932-24-006671","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006671/form4.xml","form_type":"4"}},{"id":1395471,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-10-02T20:30:20.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":1666667,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share."}],"balance_after":1666667,"derivative":{"exercise_price":0.12,"exercise_date":"2024-09-23","expiration_date":"2028-09-22","underlying":"Common Stock","underlying_shares":1666667},"source":{"system":"sec-edgar","filing":"0001477932-24-006161","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006161/form4.xml","form_type":"4"}},{"id":1395470,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-10-02T20:30:20.000Z","date":"2024-09-23","kind":"purchase","planned":false,"acquired":true,"shares":1666667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2024, the Company entered into a Securities Purchase Agreement with Mr. Imhoff pursuant to which, for an aggregate purchase price of $150,000, the Company issued 1,666,667 shares of its common stock and warrants to purchase an aggregate of 1,666,667 shares of common stock. The warrants were immediately exercisable upon issuance, expire four years following the issuance date and have an exercise price of $0.12 per share."}],"balance_after":7075898,"source":{"system":"sec-edgar","filing":"0001477932-24-006161","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224006161/form4.xml","form_type":"4"}},{"id":1413120,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2024-09-06T21:33:01.000Z","date":"2024-07-31","kind":"other","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 31, 2024, the Company issued a $25,000 note payable to Mr. Imhoff. In conjunction with the note, the Company also issued four-year warrants to purchase an aggregate of 25,000 shares of Common Stock at $0.25 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On July 31, 2024, the Company issued a $25,000 note payable to Mr. Imhoff. In conjunction with the note, the Company also issued four-year warrants to purchase an aggregate of 25,000 shares of Common Stock at $0.25 per share."}],"balance_after":25000,"derivative":{"exercise_price":0.25,"exercise_date":"2024-07-31","expiration_date":"2028-07-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001477932-24-005592","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224005592/form4.xml","form_type":"4"}},{"id":1413119,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2024-09-06T21:33:01.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth of the shares subject to the award vested on July 9, 2024; the remaining shares will vest monthly, starting on October 9, 2024, subject to the reporting person's continued service on each such date, until the award is fully vested on July 8, 2027."}],"balance_after":250000,"derivative":{"exercise_price":0.12,"expiration_date":"2034-07-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-24-005592","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224005592/form4.xml","form_type":"4"}},{"id":1425924,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T22:13:03.000Z","date":"2024-08-21","kind":"other","planned":false,"acquired":true,"shares":183008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1093."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1093."}],"balance_after":5409231,"source":{"system":"sec-edgar","filing":"0001477932-24-005207","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224005207/form4.xml","form_type":"4"}},{"id":1444661,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-08-01T21:08:19.000Z","date":"2024-07-15","kind":"other","planned":false,"acquired":true,"shares":48327,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1164."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1164."}],"balance_after":5226223,"source":{"system":"sec-edgar","filing":"0001477932-24-004509","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224004509/form4.xml","form_type":"4"}},{"id":1538625,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-19T10:03:14.000Z","date":"2024-04-05","kind":"other","planned":false,"acquired":true,"shares":48638,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1157."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1157."}],"balance_after":5177896,"source":{"system":"sec-edgar","filing":"0001477932-24-002247","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224002247/form4.xml","form_type":"4"}},{"id":1538624,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-04-19T10:03:14.000Z","date":"2024-03-26","kind":"other","planned":false,"acquired":true,"shares":4420,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.1361."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series F preferred stock, at a conversion price of $0.1361."}],"balance_after":5129258,"source":{"system":"sec-edgar","filing":"0001477932-24-002247","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224002247/form4.xml","form_type":"4"}},{"id":1626551,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-22T18:36:25.000Z","date":"2024-01-16","kind":"other","planned":false,"acquired":true,"shares":37324,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1507."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1507."}],"balance_after":5124838,"source":{"system":"sec-edgar","filing":"0001477932-24-000856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224000856/form4.xml","form_type":"4"}},{"id":1626550,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-22T18:36:25.000Z","date":"2023-10-16","kind":"other","planned":false,"acquired":true,"shares":37410,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1504."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.1504."}],"balance_after":5087514,"source":{"system":"sec-edgar","filing":"0001477932-24-000856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793224000856/form4.xml","form_type":"4"}},{"id":1786291,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Preferred Stock","published_at":"2023-09-07T19:53:16.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3))."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3))."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These securities consist of Series E Convertible Preferred Stock (\"Series E Preferred\") of the Issuer that are presently convertible on a 1-for-4,000 basis into Common Stock without payment or further consideration. The Series E Preferred shares are convertible at any time until 8/21/2025. The Series E Preferred has no expiration date."}],"balance_after":250,"derivative":{"exercise_price":0.25,"exercise_date":"2023-08-11","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001477932-23-006714","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223006714/form4.xml","form_type":"4"}},{"id":1786290,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-07T19:53:16.000Z","date":"2023-08-21","kind":"other","planned":false,"acquired":true,"shares":112568,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.1777."}],"balance_after":5050104,"source":{"system":"sec-edgar","filing":"0001477932-23-006714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223006714/form4.xml","form_type":"4"}},{"id":1786289,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-07T19:53:16.000Z","date":"2023-08-11","kind":"purchase","planned":false,"acquired":true,"shares":500899,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3))."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"These shares were issued as part of Common Stock Purchase Agreement signed between Dr. Imhoff and Rosalind Master Fund, LLP, on August 3, 2023. For a price of $150,090, Dr. Imhoff purchased 500,899 shares of Guided Therapeutics' (GTHP) common stock, par value $0.001 and 250 shares of GTHP Series E Convertible Preferred Stock (see (3))."}],"balance_after":4937536,"source":{"system":"sec-edgar","filing":"0001477932-23-006714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223006714/form4.xml","form_type":"4"}},{"id":1786288,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-09-07T19:53:16.000Z","date":"2023-07-17","kind":"other","planned":false,"acquired":true,"shares":26301,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2139."}],"balance_after":4436637,"source":{"system":"sec-edgar","filing":"0001477932-23-006714","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223006714/form4.xml","form_type":"4"}},{"id":1844585,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T16:21:49.000Z","date":"2023-04-18","kind":"other","planned":false,"acquired":true,"shares":22393,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2512."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"These shares were issued for payment of accrued dividends on the reporting individual's Series D preferred stock, at a conversion price of $0.2512."}],"balance_after":4410336,"source":{"system":"sec-edgar","filing":"0001477932-23-004759","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223004759/form4.xml","form_type":"4"}},{"id":1844583,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Options","published_at":"2023-06-26T16:21:02.000Z","date":"2023-02-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"One-fourth of the shares subject to the award vested on February 10, 2023; the remaining shares will vest monthly, subject to the reporting person's continued service on each such date, until the award is fully vested on February 9, 2026."}],"balance_after":100000,"derivative":{"exercise_price":0.26,"exercise_date":"2023-02-10","expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001477932-23-004758","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223004758/form4.xml","form_type":"4"}},{"id":1844582,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2023-06-26T16:19:44.000Z","date":"2022-09-01","kind":"purchase","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Imhoff pursuant to which the Company issued 500,000 shares of its common stock, four-year warrants to purchase an aggregate of 500,000 shares of common stock for $0.50 per share and four-year warrants to purchase 500,000 shares of common stock for $0.65 per share for an aggregate purchase price of $250,000."}],"balance_after":500000,"derivative":{"exercise_price":0.65,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-23-004757","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223004757/form4.xml","form_type":"4"}},{"id":1844581,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrants","published_at":"2023-06-26T16:19:44.000Z","date":"2022-09-01","kind":"purchase","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Imhoff pursuant to which the Company issued 500,000 shares of its common stock, four-year warrants to purchase an aggregate of 500,000 shares of common stock for $0.50 per share and four-year warrants to purchase 500,000 shares of common stock for $0.65 per share for an aggregate purchase price of $250,000."}],"balance_after":500000,"derivative":{"exercise_price":0.5,"exercise_date":"2022-09-01","expiration_date":"2026-09-01","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001477932-23-004757","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223004757/form4.xml","form_type":"4"}},{"id":1844580,"issuer":{"id":7610,"kind":"organization","name":"GUIDED THERAPEUTICS INC"},"owners":[{"id":53501,"kind":"person","name":"Imhoff John E","position":1,"cik":"0001348439","reported_name":"Imhoff John E","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-26T16:19:44.000Z","date":"2022-09-02","kind":"purchase","planned":false,"acquired":true,"shares":500000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 1, 2022, the Company entered into a Securities Purchase Agreements with Mr. Imhoff pursuant to which the Company issued 500,000 shares of its common stock, four-year warrants to purchase an aggregate of 500,000 shares of common stock for $0.50 per share and four-year warrants to purchase 500,000 shares of common stock for $0.65 per share for an aggregate purchase price of $250,000."}],"balance_after":4356532,"source":{"system":"sec-edgar","filing":"0001477932-23-004757","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/924515/000147793223004757/form4.xml","form_type":"4"}}]}